A detailed history of Verition Fund Management LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Verition Fund Management LLC holds 45,000 shares of CYTK stock, worth $2.35 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
45,000
Previous 50,000 10.0%
Holding current value
$2.35 Million
Previous $2.71 Million 12.29%
% of portfolio
0.01%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$51.22 - $60.16 $1.39 Million - $1.63 Million
27,098 Added 251.72%
37,863 $2 Million
Q2 2024

Aug 14, 2024

SELL
$47.86 - $75.05 $7.25 Million - $11.4 Million
-151,554 Reduced 93.37%
10,765 $583,000
Q1 2024

May 14, 2024

BUY
$63.75 - $108.06 $10.3 Million - $17.5 Million
162,319 New
162,319 $11.4 Million
Q2 2022

Aug 15, 2022

BUY
$33.93 - $48.92 $236,492 - $340,972
6,970 New
6,970 $274,000

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.92B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.